Oric Pharmaceuticals Inc
$ 13.42
14.60%
24 Feb - close price
- Market Cap 1,306,964,000 USD
- Current Price $ 13.42
- High / Low $ 13.75 / 11.75
- Stock P/E N/A
- Book Value 4.18
- EPS -1.71
- Next Earning Report 2026-03-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.40 %
- 52 Week High 14.93
- 52 Week Low 3.90
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Analyst Target Price
$21.23
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-12 | 2025-05-05 | 2025-03-10 | 2024-11-04 | 2024-08-12 | 2024-05-06 | 2024-03-11 | 2023-11-06 | 2023-08-10 | 2023-05-08 | 2023-03-16 |
| Reported EPS | -0.33 | -0.47 | -0.42 | -0.51 | -0.49 | -0.45 | -0.37 | -0.49 | -0.44 | -0.5 | -0.53 | -0.52 |
| Estimated EPS | -0.4 | -0.44 | -0.44 | -0.5084 | -0.4717 | -0.41 | -0.44 | -0.49 | -0.46 | -0.57 | -0.54 | -0.54 |
| Surprise | 0.07 | -0.03 | 0.02 | -0.0016 | -0.0183 | -0.04 | 0.07 | 0 | 0.02 | 0.07 | 0.01 | 0.02 |
| Surprise Percentage | 17.5% | -6.8182% | 4.5455% | -0.3147% | -3.8796% | -9.7561% | 15.9091% | 0% | 4.3478% | 12.2807% | 1.8519% | 3.7037% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.3669 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ORIC
2026-02-23 22:54:12
Oric Pharmaceuticals Inc. (ORIC) has announced an equity offering plan to raise up to $200 million through an authorization with underwriter Jefferies. This "shelf offering" will allow the biopharmaceutical company to issue common stock periodically to support its targeted oncology therapy pipeline. The flexible financing channel aims to optimize the company's financial structure and efficiently advance its therapeutic developments.
2026-02-23 22:54:12
Oric Pharmaceuticals (NASDAQ:ORIC) has filed a new prospectus supplement for an "at-the-market" (ATM) offering, aiming to raise up to $200 million by selling common stock. This new filing replaces a previous one from March 2024, under which the company raised approximately $139.7 million. The offering comes as Oric holds a strong balance sheet and continues to advance its oncology drug candidates, with several positive analyst coverages and promising clinical trial results for its lead drugs.
2026-02-23 21:54:12
Oric Pharmaceuticals, Inc. has released its 2025 Form 10-K report, detailing a net loss of $129.5 million and outlining its strategic focus on advancing two lead clinical-stage product candidates: Rinzimetostat and Enozertinib. The company plans to initiate a global Phase 3 trial for Rinzimetostat in early 2026 and expects its current funds to last into the second half of 2028, despite facing significant financial and developmental risks. Strategic initiatives include pipeline prioritization, workforce reduction, and capital management through various offerings to support ongoing R&D efforts.
2026-02-23 21:54:12
Oric Pharmaceuticals (NASDAQ:ORIC) announced its latest earnings, reporting an adjusted EPS of ($0.30), which surpassed the consensus estimate of ($0.33) by $0.03. Following the announcement, the stock increased by 5.4% to $11.71, valuing the company at approximately $1.14 billion. The article also notes significant institutional ownership (95.05%) and recent insider selling, alongside a "Moderate Buy" consensus rating from analysts with an average target price of $19.90.
2026-02-23 21:54:12
ORIC Pharmaceuticals (NasdaqGS:ORIC) is advancing its cancer therapy pipeline with lead drug candidates entering Phase 1b clinical trials. The company has secured new collaborations with Pfizer, Bayer, and Johnson & Johnson to tackle cancer treatment resistance, which could provide crucial funding and expertise. While these partnerships validate ORIC's strategy, the company remains unprofitable and will rely on external funding, with future clinical data and partnership milestones being key for investors to monitor.
2026-02-23 20:54:12
ORIC Pharmaceuticals reported its fourth quarter and full-year 2025 results, highlighting a strengthened financial position with $392.3 million in cash, cash equivalents, and investments as of December 31, 2025. The company raised $264 million in 2025 and an additional $20 million subsequently, extending its cash runway into the second half of 2028. Clinical data for rinzimetostat in metastatic castration-resistant prostate cancer and enozertinib in EGFR-mutated non-small cell lung cancer showed promising efficacy, with plans for Phase 3 trials and further data readouts in 2026.
